Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 10Breast Neoplasms 10Uterine Cervical Neoplasms 9Lymphoma 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Head and Neck Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Sarcoma 5Melanoma 5Lymphoma, Follicular 5Leukemia 5Colorectal Neoplasms 5Adenocarcinoma of Lung 5Small Cell Lung Carcinoma 4Rectal Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Glioblastoma 4Central Nervous System Neoplasms 4Carcinoma, Hepatocellular 4Burkitt Lymphoma 4Ovarian Neoplasms 3Neoplasms 3

Interventions

veliparib 1bavituximab 1avatrombopag 1Sorafenib 1Radiotherapy 1Radiosurgery 1Paclitaxel 1Immunotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liver Diseases × Radiotherapy × Clear all
NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡